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dosage form that disintegrates and dissolves in the mouth, 
either on or beneath the tongue or in the buccal cavity 
without water, within 60 s or lower. The US Food and 
Drug Administration (FDA) Center for Drug Evaluation 
and Research (CDER) defines, in the orange book, an 
oral disintegrating tablet as, “A solid dosage form containing 
medicinal substances, which disintegrates rapidly, usually within a 
matter of  seconds, when placed upon the tongue.” At present, oral 
disintegrating tablets are the only quick-dissolving dosage 
form recognized by FDA and listed in the approved drug 
products with therapeutic equivalence evaluations.[1,2]
The drug selected for the study was cefexime trihydrate, 
which is used in the treatment of uncomplicated urinary 
tract infections.[3,4] The aim of the study was to formulate 
an oral disintegrating tablet of cefixime trihydrate using two 
superdisintegrants separately (crosscarmellose sodium and 
sodium starch glycolate), and to select the best among the 
two based on the disintegration time and other tableting 
properties.
INTRODUCTION
Disintegrants are agents added to tablet formulations 
to promote the break-up of the tablet into smaller 
fragments in an aqueous environment, thereby increasing 
the available surface area and promoting a more rapid 
release of the drug substance. In more recent years, 
several newer disintegrants have been developed, often 
called “super disintegrants.” These newer substances 
can be used at lower levels than conventionally used 
disintegrants. Three major mechanisms and factors 
affecting tablet disintegration are suggested as swelling, 
porosity and capillary action and deformation. Three 
major group of compounds that have been developed 
as superdisintegrants are modified starches, cross-linked 
polyvinylpyrrolidone and modified cellulose.
One of the major streams of application of superdisintegrants 
is in the formulation of oral disintegrating tablets/mouth 
dissolving tablets. An oral disintegrating tablet is a solid 
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MATERIALS AND METHODS
Materials
Cefixime trihydrate was procured from Aurobindo Pharma 
Ltd . Sodium starch glycolate and croscarmellose sodium 
were procured from DK Enterprises, while magnesium 
stearate and talc was from Nice Chemicals .
Methodology
Preformulation studies[5-7]
Preformulation study is defined as an investigation of 
the physical and chemical properties of drug substance 
alone and when combined with the excipients. The 
overall objective of preformulation testing is to generate 
information useful to the formulator in developing a stable 
and bioavailable dosage form that can be mass produced. 
The commonly investigated preformulation parameters 
include angle of repose, bulk density/tapped density, pour 
density, Carr’s compressibility index and Hausner ratio.
Angle of  repose
It is determined by allowing a powder to flow through 
a funnel and fall freely on to a surface. Further addition 
of powder is stopped as soon as the pile touches the tip 
of the funnel. A circle is drawn around the pile without 
disturbing it. The height and diameter of the resulting cone 
are measured. The same procedure is repeated three times 
and the average value is taken. Angle of repose is calculated 
by using the following equation:
Tan θ = h/r
Where, h = height of the powder cone; r = radius of the 
powder
Bulk density
Unless otherwise specified, pass a quantity of material 
sufficient to complete the test through a 1.00-mm (no. 18) 
screen to break up agglomerates that may have formed 
during storage. Into a dry 250-ml cylinder introduce, without 
compacting, approximately 100 g of the test sample (M) 
weighed with 0.1% accuracy. If it is not possible to use 
100 g, the amount of the test sample and the volume of 
the cylinder may be modified. Select a sample mass having 
an untapped apparent volume of 150–250 ml. A 100-ml 
cylinder is used for apparent volumes between 50 and 100 
ml. Fill the cylinder carefully. Carefully level the powder 
without compacting, if necessary, and read the unsettled 
apparent volume (Vo). Calculate the bulk density, in g/ml, 
using the formula,
Bulk density = M/Vo
Tapped density
Accurately weighed quantity of powder is introduced 
into a measuring cylinder. Mechanically tap the cylinder 
containing the sample by raising the cylinder and allowing 
it to drop under its own weight using a suitable mechanical 
tapped density tester at a nominal rate of 300 drops/min. 
Tap the cylinder 500 times and measure the tapped volume 
(Va). Repeat the operation for an additional 750 tappings 
and again measure the tapped volume as (Vb).
If the difference between Va and Vb is <2%, Vb is the final 
tapped volume (Vf). If the difference is higher, repeat the 
tapings for an additional 1,250 times, and then the tapped 
density can be calculated using the following formula 
(United States pharmacopoeia, 2004)
Tapped density = M/Vf
Where, M = weight of the sample taken; Vf = final tapped 
volume
Carr’s index
The compressibility index of granules can be determined 
using Carr’s compressibility index, and can be determined 
by the following formula:
                               
(Tapped density –
 
                                 
  Pour density)
Carr’s index (%)   =    
 Tapped density
        X 100
Hausner ratio
The Hausner ratio can be determined using the following 
formula:
Hausner ratio (%) = 
 Tapped density  
X 100
                 Pour density
Compatibility studies
IR  studies of drug and drug with superdisintegrants were 
carried out in order to check the compatibility between the 
drug and the excipients.
Formulation development
The methodology selected for the preparation of cefixime 
oral disintegrating tablets is direct compression. About 10 
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formulations were prepared, of which five formulations 
included varying concentrations of the superdisintegrant 
sodium starch glycolate and five of crosscarmellose 
sodium. The list of ingredients is given in  Tables 1 and 2.
Tablet evaluation[8-10]
The selected batches made in bulk were subjected to 
evaluations as per Indian pharmacopoeia.
Weight variation
Twenty tablets were selected at random, weighed and the 
average weight was calculate. Not more than two of the 
individual weights should deviate from the average weight 
by more than 5%.
Friability
For each formulations, preweighed tablet samples (20 
tablets) were placed on the friabilator, which is then 
operated for 100 revolutions. The tablets were then 
dusted and reweighed. Conventional compressed tablets 
that loose <0.5–1.0% of their weight are considered 
acceptable.
Hardness
Tablet hardness of each formulation was determined using 
a Monsanto hardness tester . Results were calculated from 
the average results of six tablets.
Thickness
Tablet thickness is determined using vernier calipers. 
Six tablets were evaluated to determine the average 
thickness.
Disintegration test
Introduce one tablet into each tube and add a disc to each 
tube. Suspend the assembly in the beaker containing the 
specified liquid and operate the apparatus for a specified 
period of time. The tablet passes the test if all tablets have 
disintegrated. If one or two tablets fail to disintegrate, 
repeat the test on 12 additional tablets, such that not <16 
of the total of 18 tablets tested disintegrate. If the tablets 
adhere to the disc, repeat the test by omitting the disc. The 
preparation complies with the test if all the tablets in the 
repeat test disintegrate.
Dissolution studies/in vitro release studies
Medium
0.05 M potassium phosphate buffer, pH 7.2, prepared by 
dissolving 6.8 g of monobasic potassium phosphate in 
1,000 ml of water and adjusting with 1N sodium hydroxide 
to a pH of 7.2, 900 ml.
Apparatus
Dissolution apparatus with 100 rpm.
Time
Forty-five minutes.
Procedure
The amount of cefixime released was determined by 
measuring the absorbance of the sample withdrawn at 
280 nm in comparison with a standard solution having a 
Table 1: Formulation of cefixime with sodium starch glycolate
Ingredients S 1( mg) S2(mg) S3(mg) S4(mg) S5(mg)
Cefixime trihydrate   55.90 55.90 55.90 55.90 55.90
Microcrystalline cellulose  214.30 211.50 - - 217.10
Pregelatinised starch - - 214.30 211.50 -
Sodium starch glycolate 5.60 8.40 5.60 8.40 2.80
Magnesium stearate 1.40 1.40 1.40 1.40 1.40
Talc 2.80 2.80 2.80 2.80 2.80
Average weight ( mg) 280.00 280.00 280.00 280.00 280.00
Table 2: Formulation of cefixime with cross carmellose sodium
Ingredients C 1( mg) C2(mg) C3(mg) C4(mg) C5(mg)
Cefixime trihydrate   55.90 55.90 55.90 55.90 55.90
Microcrystalline cellulose  214.30 211.50 - - 217.10
Pregelatinised starch - - 214.30 211.50 -
Sodium starch glycolate 5.60 8.40 5.60 8.40 2.80
Magnesium stearate 1.40 1.40 1.40 1.40 1.40
Talc 2.80 2.80 2.80 2.80 2.80
Average weight ( mg) 280.00 280.00 280.00 280.00 280.00
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known concentration of USP cefixime reference standard 
(RS) in the same medium.
RESULTS AND DISCUSSION
Preformulation studies
Values of the preformulation studies are given in Table 3, 
from which it is evident that all the parameters analyzed 
showed satisfactory flow properties and compression 
characteristics.
Compatibility studies
IR spectra of cefixime, sodium starch glycolate, 
crosscarmellose sodium and combinations are given in 
Figures 1–5. The results of the FTIR  spectral analysis 
showed that the peaks and the pattern of the spectra 
were similar in all cases, which indicated that there was no 
chemical interaction or decomposition of cefixime during 
the preparation of the tablets.
Formulation
Because the aim of the project was to formulate cefixime 
50 mg DT tablet, which disintegrated within 1 min, priority 
was given so as to get good results with cost-effectiveness 
of the product.
From the tables and histograms, it was evident that the 
formulations C1 and S3 stood ahead in all the tableting 
properties and in disintegration performance. Both the 
batches were prepared in bulk [Table 4] and confirmatory 
evaluation tests were carried out.
DT  stands satisfactory with the time limit of <1 min for all 
Table 3: Physicochemical evaluation of the 
formulations
Parameters  Formulation with 
cross carmellose 
mean value of 
(C1 – C5)
Formulation with 
sodium starch 
glycollate  
(S1 – S5)
Angle of repose  24 ° 37’ 2.1’’ 27°  25’ 13.02’’
Bulk density / tapped 
density
0.6517 0.7117
Pour density  0.5140 0.5761
Carr’s compressibility index  21.12 19.05
Hausner ratio 1.26 1.23
Table 4: Tablet ingredients for scale up batch
Ingredients Quantity/
tablet (mg)
Quantity 
for 50 
tablets (g) 
(S3)
Quantity 
for 50 
tablets (g) 
(C 1)
Cefixime trihydrate 55.90 2.795 2.795
Microcrystalline 
cellulose
214.30 10.715 10.715
Sodium starch glycolate 5.60 0.280 ----
Cross carmellose sodium 5.60 ---- 0.280
Magnesium stearate 1.40 0.070 0.070
Talc 2.80 0.140 0.140
Pineapple flavor q.s  q.s q.s
Tarazarine lake q.s q.s q.s
Average weight (mg) 280.00 ---- ----
Table 5: Evaluation parameters of the best 
formulations
Tablet evaluation 
parameters
Formula S3 Formula C1
Diameter 0.96 0.95
Thickness 0.36 0.38
Hardness 3.0 3.5
Friability 0.751 0.725
Weight variation pass pass
Disintegration time (sec) 42 32
Dissolution rate (%) 94.56 96.37
Table 6: Evaluation of tabletting parameters
Tablet parameters Formula S1 Formula S2 Formula S3 Formula S4 Formula S5
Thickness (cm) 0.37 0.37 0.36 0.38 0.36
Hardness (kg/cm2) 2.6 2.8 3.0 2.6 2.6
Friability (%)  0.750 0.751 0.526 0.640 0.575
Table 7: Evaluation of tabletting parameters
Tablet parameters Formula C1 Formula C2 Formula C3 Formula C4 Formula C5
Thickness(cm) 0.38 0.37 0.37 0.36 0.37
Hardness (kg/cm2) 2.8 2.8 2.6 2.4 2.6
Friability (%) 0.538 0.751 0.752 0.638 0.575
Table 8: Disintegration profile of the formulations
Formula S1 S2 S3 S4 S5 C1 C2 C3 C4 C5
Disintegration time in seconds 65 60 42 50 54 35 45 48 49 53
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the batches, as shown in Figures 6 and 7. Now, the question 
exists for fixing the best batch among the rest. Hence, for 
the comparative study, one with the same percentage was 
selected (2%). The batches S3 and C1 were selected to carry 
out further evaluation [Table 5].
Evaluation of tableting properties of the selected batches 
confirm the standards prescribed in Indian pharmacopoeia. 
The results are given in Tables 6 and 7.
Disintegration time was found to be within 1 min and 
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Figure 1: IR spectrum of cefixime
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Figure 3: IR spectrum of sodium starch glycollate
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Figure 5: IR spectrum of cefixime tablet blend with sodium starch 
glycolate
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Figure 2: IR spectrum of crosscarmellose sodium
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Figure 4: IR spectrum of cefixime tablet blend with crosscarmellose 
sodium
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Figure 6: Disintegration profile of the selected batch
0
20
40
60
80
S1 S2 S3 S4 S5
Formulations
T
i
m
e
 
i
n
 
s
e
c
o
n
d
sJ Young Pharm Vol 2 / No 3  239
the percentage drug release, which confirms the in vitro 
bioavailability, was found to be 94.56 and 96.37, respectively, 
for S3 and C1, which proves the credibility of the selected 
products. The results are given in Table 8.  
With reference to Table 5, a comparison of the different 
parameters like hardness, friability, disintegration and 
dissolution was carried out and superiority of the tablets 
formulated with crosscarmellose was established.
CONCLUSION
The aim of the present project is formulation development, 
evaluation and comparative study of superdisintergrants in 
the Cefixime 50 mg oral disintegrating tablet.
Figure 7: Disintegration profile of the selected batch
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With the proof of different evaluation parameters listed 
in Table 8, it was concluded that C3 (CCS) was the best 
formulation.
Comparative evaluation studies proved that crosscarmelose 
is superior to sodium starch glycolate.
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